麻酔誘導後のタコツボ心筋病

Danielle D Strah¹, Peter Chau¹, Branden M Engorn^2,3

¹Department of Pediatrics, Division of Cardiology, University of California, San Diego Rady Children's Hospital, San Diego, USA.

Cardiology in the young

|August 29, 2025

まとめ

タコツーボ心筋症候群は子供にも起こり得るこの症例は麻酔後にストレス性心筋病を発症した 11歳の男の子の詳細で希少な小児薬の相互作用を強調しています

科学分野:

心臓病科
小児医学
麻酔科

背景:

タコツボ心筋病症はストレス心筋病症または壊れた心臓症候群としても知られており,オクトパストラップに似た特定の心声検査の発見によって特徴付けられています.
通常は高齢の女性と感情的苦痛に関連していますが,小児の集団ではますます認識されています.
この状態は診断と管理に独特の課題をもたらします

研究の目的:

タコツボ心筋病の珍しい症例を報告する
麻酔誘導中のストレス性心筋病変を引き起こす異常な薬物相互作用を記述する.
小児科におけるタコツボ心筋病の発生を強調し,その既知の臨床スペクトルを拡大する.

主な方法:

11歳の男性で複雑な病歴があります
患者のプレゼンテーション,麻酔の経過,心停止の詳細なレビュー.
タコツーボ心筋病の診断を確認するエコーカルディオグラフィの評価
麻酔剤と潜在的薬物相互作用の分析

主要な成果:

患者は麻酔の誘導中に心臓発作を起こした.
タコツボの心臓筋病は成功した蘇生後に診断された.
異常な薬物相互作用が,このイベントの引き金として特定されました.
これは,この特定の薬物相互作用に関連したTakotsubo心筋病の報告された最初の小児症例です.

結論:

タコツーボ心筋病は,複雑な病歴を持つ小児患者でも発生する.
麻酔の管理には,ストレス性心筋病を引き起こす可能性のある薬物相互作用を慎重に考慮する必要があります.
このケースは,小児重症病院でのタコツーボ心筋病の認識と管理の重要性を強調しています.

キーワード:

タコツボ心臓発作心臓機能障害心筋病

さらに関連する動画

08:28

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice

Published on: January 19, 2022

7.2K

08:01

Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System

Published on: June 11, 2020

8.2K

関連する概念動画

01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...

01:26

Heart Failure Drugs: Inotropic Agents

717

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

717

01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

関連する実験動画